Biogen Call for Proposals for Residency at LabCentral


As a leader in neuroscience, Biogen seeks to engage with those who are championing revolutionary ideas in multiple areas of neuroscience as well as next generation of drug discovery technologies and platforms.


External Portfolio Innovation Unit

The External Portfolio Innovation Unit (EPIU) represents Biogen by establishing a global network with industry, academia and others to foster external collaborations, driving innovation while strengthening the neuroscience ecosystem.



LabCentral is a first-of-its-kind, shared laboratory space designed to launch life science and biotech start-ups. LabCentral provides the infrastructure entrepreneurs and innovators need to test out, challenge and nurture their ideas.

As a platinum sponsor, Biogen’s EPIU can nominate up to two early-stage companies each year to take up residence in LabCentral's Kendall Square facilities. Each Biogen-LabCentral Golden Ticket includes up to one year of bench space for one scientist and the benefits of LabCentral's shared infrastructure and services at no cost to the contest winner. See  

Special consideration will be provided to proposals focused on neuroscience, neurodegeneration and areas related to Biogen research.


Competition Rules, Eligibility and Judging Criteria

Applicants for the Biogen-LabCentral Golden Ticket Competition will need to submit an application following the link below. More information can be found under Eligibility criteria, terms and conditions.

Previous winners of Biogen Golden Tickets were: Amathus Therapeutics and Braizon Therapeutics.

Companies meeting the eligibility criteria can submit an application following the link below including a brief non-confidential proposal by 11:59 PM, Eastern Time, on October 14th.


Golden Ticket Competition Application

Eligibility criteria, terms and conditions apply



Guillermo Yudowski

Principal Investigator, External Portfolio Innovation Unit (EPIU)

Biogen | 225 Binney Street | Cambridge, MA | 02142